Clinical Trials Logo

Pleural Effusion, Malignant clinical trials

View clinical trials related to Pleural Effusion, Malignant.

Filter by:

NCT ID: NCT03276715 Completed - Lung Cancer Clinical Trials

Prognostic Factors on Malignant Pleural Effusion

Start date: June 1, 2016
Phase:
Study type: Observational [Patient Registry]

Malignant pleural effusion can occur in up to half of the patients with metastatic disease. It can cause shortness of breath to patients and so far there is no protocol on its management. The study is looking at patients with malignant pleural effusion and aims to identify its prognostic factors. Pleural fluid and blood analysis will be performed as in the standard of care and results will be collected at the start of diagnosis. This will not affect subsequent management plan. Patients' disease course will be followed up and progress data will be collected. Data will then be analysed to identify relevant prognostic factors.

NCT ID: NCT03272997 Completed - Clinical trials for Pleural Effusion, Malignant

The Value of PET-CT in Pleural Effusions

Start date: October 1, 2017
Phase:
Study type: Observational

The investigators aim is to asses the diagnostic power of 18F-FDG PET-CT in discriminating malignant from nonmalignant causes in patients with a recurrent unilateral pleural effusion of unknown origin.

NCT ID: NCT03270215 Completed - Clinical trials for Pleural Effusion, Malignant

The Added Value of CT Scanning in Patients With an Unilateral Pleural Effusion

Start date: October 1, 2017
Phase:
Study type: Observational

To investigate the diagnostic power of computed tomography for discriminating malignant from nonmalignant causes to pleural effusions in consecutive patients with no malignant cells found at a cytological examination and a chest x-ray not suspicious of malignancy. The investigators hypothesised that the combination improves the chance of detecting the cause of the pleural effusion.

NCT ID: NCT03235999 Recruiting - Clinical trials for Malignant Pleural Effusion

The Experiences of Patients Living With Malignant Pleural Effusions

Start date: July 2016
Phase:
Study type: Observational

Up to 20 patients with malignant pleural effusions will be interviewed about their experiences of having this condition and its management.

NCT ID: NCT02975921 Withdrawn - Pleural Effusion Clinical Trials

Betadine Pleurodesis Via Tunneled Pleural Catheters

Start date: July 2018
Phase: Phase 4
Study type: Interventional

The purpose of this study is to determine whether betadine (povidone-iodine) instillation during routine indwelling Tunneled Pleural Catheter (TPC) placement is efficacious in promoting pleurodesis and thus reducing the time to TPC removal.

NCT ID: NCT02942043 Recruiting - Clinical trials for Malignant Pleural Effusion

Bevacizumab in the Treatment of Malignant Pleural Effusions of Non-squamous Non-small Cell Lung Cancer

Start date: October 2016
Phase: Phase 2
Study type: Interventional

The purpose of this study is to explore the efficacy and safety of different doses of bevacizumab injection in the treatment of malignant pleural effusion in patients with advanced non-squamous non-small cell lung cancer.

NCT ID: NCT02825095 Not yet recruiting - Lung Neoplasms Clinical Trials

Management of Malignant Pleural Effusion - Indwelling Pleural Catheter or Talc Pleurodesis

Start date: August 2016
Phase: Phase 0
Study type: Interventional

Prospective study of the effect of Talc Pleurodesis vs. Indwelling Pleural catheter in treatment of patients with malignant pleural effusion

NCT ID: NCT02805062 Not yet recruiting - Clinical trials for Pleural Effusion, Malignant

Manometry vs Clinical Assessment in the Detection of Trapped Lung in Patients With Suspected Pleural Malignancy

MASCOT
Start date: June 2016
Phase: N/A
Study type: Observational

Malignant pleural effusion is a common clinical problem with median survival of approximately 6 months thus efficient management of Malignant pleural effusion is important. In patients with a Trapped Lung, pleurodesis will be unsuccessful and an indwelling pleural catheter should be inserted instead. Accurate detection of Trapped Lung prior to insertion would avoid futile attempts at talc pleurodesis, re-intervention following failed pleurodesis and allow adequate time to plan for an indwelling pleural catheter insertion.Pleural manometry allows direct and objective measurement of intra-pleural pressure during pleural fluid aspiration.The primary aim of this study is to determine whether the addition of digital pleural manometry to clinical judgment, prior to and during local anaesthetic thoracoscopy, results in a clinically meaningful improvement in Trapped Lung detection.

NCT ID: NCT02702700 Terminated - Clinical trials for Pleural Effusion, Malignant

Photo-induction as a Means to Improve Cisplatin Delivery to Pleural Malignancies

PDT-lipo
Start date: January 2016
Phase: Phase 1
Study type: Interventional

This clinical study aims to explore intrapleural low-dose Visudyne®-mediated photodynamic therapy (photo-induction) as a pathway to promote the uptake of systemically administered Lipoplatin™ in pleural malignancies of patients undergoing video-assisted talcage for their malignant pleural effusions. Photo-induction is expected to overcome the chemo-resistance of pleural malignancies for cisplatin-based chemotherapeutics and thereby improve local tumor control.

NCT ID: NCT02674243 Completed - Clinical trials for Malignant Pleural Effusion

Efficacy of Iodopovidone Versus Talc in Palliative Malignant Pleural Effusion

Start date: November 2015
Phase: Phase 3
Study type: Interventional

This is prospective randomized control trial study. The aim of this study is to evaluate the efficacy of Iodopovidone solution for pleurodesis in palliative malignant pleural effusion (MPE) patients comparing to Talc. All adult patients who diagnosed MPE by cytology regardless primary tumor between December 1, 2015 and November 29, 2016 at Maharaj Nakorn Chiang Mai Hospital, Chiang Mai University, Chiang Mai, Thailand will be enrolled in this study. The inform and consent will be applied in all patients before treatment. Patients will be randomized to two groups; Iodopovidone group (intervention group) and Talc group (control group)